Literature DB >> 2848532

Suppression of monosodium urate crystal-induced acute inflammation by diets enriched with gamma-linolenic acid and eicosapentaenoic acid.

G A Tate1, B F Mandell, R A Karmali, M Laposata, D G Baker, H R Schumacher, R B Zurier.   

Abstract

A subcutaneous air pouch formed in Sprague-Dawley rats was used to study the effect of diets enriched in gamma-linolenic acid (GLA) (in plant seed oil) and eicosapentaenoic acid (EPA) (in fish oil) on acute inflammation induced by monosodium urate crystals. The GLA-enriched diet suppressed significantly the cellular phase of inflammation (polymorphonuclear leukocyte accumulation, crystal phagocytosis, and lysosomal enzyme activity), but it had little effect on the fluid phase (exudate volume and protein concentration). In contrast, the EPA-enriched diet suppressed the fluid phase but not the cellular phase of inflammation. The findings indicate that the fluid and cellular phases of acute inflammation can be controlled independently. A combined diet of fish oil and plant seed oil (EPA-enriched and GLA-enriched) reduced both the cellular and fluid phases of inflammation. Thus, dietary provision of alternative substrates for oxidative metabolism (other than arachidonic acid) modifies monosodium urate crystal-induced acute inflammation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848532     DOI: 10.1002/art.1780311211

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  17 in total

1.  gamma-Linolenic acid-containing diet attenuates bleomycin-induced lung fibrosis in hamsters.

Authors:  V A Ziboh; M Yun; D M Hyde; S N Giri
Journal:  Lipids       Date:  1997-07       Impact factor: 1.880

Review 2.  Diet, alcohol, and gout: how do we advise patients given recent developments?

Authors:  Hyon K Choi
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

Review 3.  Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids.

Authors:  J M Kremer
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

4.  Changes of fatty acid composition and oxidative metabolism of human neutrophils migrating into an inflammatory exudate.

Authors:  A Carletto; P Bellavite; P Guarini; D Biasi; S Chirumbolo; P Caramaschi; L M Bambara; R Corrocher
Journal:  Inflammation       Date:  1996-04       Impact factor: 4.092

5.  Potential anti-inflammatory actions of the elmiric (lipoamino) acids.

Authors:  Sumner H Burstein; Jeffrey K Adams; Heather B Bradshaw; Cristian Fraioli; Ronald G Rossetti; Rebecca A Salmonsen; John W Shaw; J Michael Walker; Robert E Zipkin; Robert B Zurier
Journal:  Bioorg Med Chem       Date:  2007-03-13       Impact factor: 3.641

6.  Effect of Dietary and Supplemental Omega-3 Polyunsaturated Fatty Acids on Risk of Recurrent Gout Flares.

Authors:  MaryAnn Zhang; Yuqing Zhang; Robert Terkeltaub; Clara Chen; Tuhina Neogi
Journal:  Arthritis Rheumatol       Date:  2019-08-01       Impact factor: 10.995

7.  Effects of altering the eicosanoid precursor pool on neovascularization and inflammation in the alkali-burned rabbit cornea.

Authors:  L D Ormerod; A Garsd; M B Abelson; K R Kenyon
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

8.  Suppression of interleukin 2-dependent human T cell growth in vitro by prostaglandin E (PGE) and their precursor fatty acids. Evidence for a PGE-independent mechanism of inhibition by the fatty acids.

Authors:  D Santoli; P D Phillips; T L Colt; R B Zurier
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

9.  Suppression of monosodium urate crystal-induced inflammation by black currant seed oil.

Authors:  G A Tate; R B Zurier
Journal:  Agents Actions       Date:  1994-11

10.  Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia.

Authors:  Vanessa C Vaughan; Melanie Sullivan-Gunn; Edward Hinch; Peter Martin; Paul A Lewandowski
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.